HEMATIDE Canadian Trademark Information
Pharmaceuticals for use in stimulating human blood cell production; pharmaceuticals for the treatment of cancer, anemia, ischemia, myocardial infarction, congestive heart failure, renal failure, anoxia-induced cellular degeneration, hypoxia-induced cellular degeneration and stroke.Pharmaceuticals for use in stimulating human blood cell production; pharmaceuticals for the treatment of cancer, anemia, ischemia, myocardial infarction, congestive heart failure, renal failure, anoxia-induced cellular degeneration, hypoxia-induced cellular degeneration and stroke. Pharmaceuticals for use in stimulating human blood cell production; pharmaceuticals for the treatment of cancer, anemia, ischemia, myocardial infarction, congestive heart failure, renal failure, anoxia-induced cellular degeneration, hypoxia-induced cellular degeneration and stroke.
Perfect for these industries
Words that describe this mark
pharmaceuticals use stimulating human blood cell production pharmaceuticals treatment cancer anemia ischemia myocardial infarction congestive heart failure renal failure anoxiainduced cellular degeneration hypoxiainduced cellular degeneration strokepharmaceuticals use stimulating human blood
Abandonment Notice!
On Wednesday, June 4, 2014,
status on the HEMATIDE
trademark changed to Interruption of proceeding.
Apply Now for this name starting at $449!
CAUTION: Although Canada registration for this particular filing is inactive,
the mark may still enjoy common law rights, or may have been applied for again in a separate application.
Further research may be warranted to determine where this mark is truly abandoned in commerce.
On Tuesday, May 17, 2011, a canadian trademark registration was filed for
HEMATIDE by Affymax, Inc. *********, **********, ***** ****.
The Canadian IP office has given the trademark application number of
1528151.
The current status of this trademark filing is Interruption of proceeding.
The HEMATIDE
trademark is filed in the description of
Pharmaceuticals for use in stimulating human blood cell production; pharmaceuticals for the treatment of cancer, anemia, ischemia, myocardial infarction, congestive heart failure, renal failure, anoxia-induced cellular degeneration, hypoxia-induced cellular degeneration and stroke.
,
Pharmaceuticals for use in stimulating human blood cell production; pharmaceuticals for the treatment of cancer, anemia, ischemia, myocardial infarction, congestive heart failure, renal failure, anoxia-induced cellular degeneration, hypoxia-induced cellular degeneration and stroke.
,
Pharmaceuticals for use in stimulating human blood cell production; pharmaceuticals for the treatment of cancer, anemia, ischemia, myocardial infarction, congestive heart failure, renal failure, anoxia-induced cellular degeneration, hypoxia-induced cellular degeneration and stroke.
.
100% Satisfaction Guarantee
protect your valuable brand now.
Classification Information
Trademarkia is the largest search engine for U.S., China, European Union, Canada, and Australia Trademarks.
Each month hundreds of trademarks around the world are filed by licensed attorneys in the Trademarkia network law firms!
You can
register your trademark in 180+ countries
in the world through Trademarkia Network. Trademarkia.com is a free search engine of publicly available government records.
Trademarkia.com is not a law firm and does not represent owners & correspondents listed on this page.